Antimicrobial effect of fluoroquinolones for the eradication of nontypeable Haemophilus influenzae isolates within biofilms.
Biofilms can be defined as communities of microorganisms attached to a surface. Those bacterial biofilms cause serious problems, such as antibiotic resistance and medical device-related infections. Nontypeable Haemophilus influenzae (NTHi) is an important pathogen in respiratory infections, as it forms biofilms both in vitro and in vivo such as human middle ear. Recent reports indicate that otitis media, paranasal sinusitis and lower respiratory tract infections caused by Haemophilus influenzae have become more difficult to treat with oral antibiotic therapy. However, there has been no attention given to antibiotic eradication of NTHi biofilm. To investigate the antimicrobial effect of various antibiotics against NTHi biofilm formation, we conducted the following comparative study using both beta-lactamase-negative ampicillin (AMP)-susceptible (BLNAS) and AMP-resistant (BLNAR) NTHi strains. In a microtiter biofilm assay, both levofloxacin and gatifloxacin, of the fluoroquinolone antibiotic group, significantly inhibited biofilm formation by BLNAS and BLNAR NTHi in a dose-dependent fashion compared to ampicillin of the penicillin antibiotic group, cefotaxime of the cephalosporin antibiotic group, and both erythromycin and clarithromycin of the macrolide antibiotic group. Furthermore, in flow cell chamber studies, confocal laser scanning microscopy counted survival bacteria in mature biofilm had been treated with gatifloxacin, ampicillin, cefotaxime and erythromycin. Only gatifloxacin completely killed the BLNAR NTHi isolates within biofilms without regard to the thickness of biofilm formation. The results of this study suggest that fluoroquinolones potentially have a role in therapy against diseases caused by both BLNAS and BLNAR NTHi isolates within biofilms.
Kaji
Chiharu
C
Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
Watanabe
Kiwao
K
Apicella
Michael A
MA
Watanabe
Hiroshi
H
D000667:Ampicillin / Q000494:pharmacology; D000668:Ampicillin Resistance / Q000187:drug effects; D000890:Anti-Infective Agents / Q000494:pharmacology*; D015373:Bacterial Typing Techniques / Q000379:methods*; D018441:Biofilms / Q000187:drug effects*; D018533:Biomass; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D024841:Fluoroquinolones / Q000494:pharmacology*; D000077734:Gatifloxacin; D006193:Haemophilus influenzae / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification* / Q000502:physiology; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases / Q000494:pharmacology
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D000667:Ampicillin; D001618:beta-Lactamases; D000077734:Gatifloxacin